PTC Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• PTC Therapeutics Inc PTCT.OQ reported quarterly adjusted earnings of 43 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 66 cents per share. Wall Street expected results to range from $-1.45 to 99 cents per share.

• Revenue fell 30.6% to $213.17 million from a year ago; analysts expected $232.44 million.

• PTC Therapeutics Inc's reported EPS for the quarter was a loss of 85 cents​.

• The company reported a quarterly loss of $65.89 million.

• PTC Therapeutics Inc shares had risen by 12.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 38.2% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and 3 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for PTC Therapeutics Inc is $62.50

This summary was machine generated from LSEG data February 27 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)